Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer Vaccine at ASCO's 2005 Annual Meeting
05 Abril 2005 - 12:01AM
PR Newswire (US)
Transgene to Present Phase II Data of Its MVA-UC1-IL2 Cancer
Vaccine at ASCO's 2005 Annual Meeting STRASBOURG, France, April 5
/PRNewswire-FirstCall/ -- Transgene (Nasdaq: TRGNY; Eurolist Paris:
FR0005175080) announced today that data from the MVA-MUC1-IL2
cancer vaccine Phase II trials in non-small cell lung and prostate
cancers has been accepted for presentation at the 2005 Annual
Meeting of ASCO (American Society of Clinical Oncology). The
meeting will take place in Orlando, Florida, May 13-17, 2005. 1.
Poster presentation: "A Phase II study evaluating the clinical
efficacy of MVA-MUC1-IL2 (TG4010) in association with chemotherapy
in patients with Non Small Cell Lung Cancer". Presented by Prof.
Thierry Velu, Academic Erasme Hospital, Brussels, Belgium. 2. Oral
presentation in the genito-urinary scientific program: "MVA-MUC1-
IL2 vaccine immunotherapy (TG4010) in patients with prostate cancer
with biochemical failure". Presented by Dr. Robert Dreicer,
Cleveland Clinic Foundation, Cleveland, Ohio. "We are very pleased
that two abstracts describing clinical results with our cancer
vaccine MVA-MUC1-IL2 have been selected for presentation at this
year's ASCO meeting," said Dr. Patrick Squiban, MD, VP, Medical and
Regulatory Affairs of Transgene. "It will be an opportunity to
communicate updated, additional data beyond the promising interim
results that we have released up to now." About Transgene:
Transgene, based in Strasbourg, France, is a biopharmaceutical
company dedicated to the discovery and development of therapeutic
vaccines and immunotherapy products for the treatment of cancer and
infectious diseases. Transgene has a broad portfolio of products in
clinical development. This press release contains a forward-looking
statement regarding the potential efficacy of one of Transgene's
cancer vaccine candidates. The results of clinical testing to date
are preliminary and based upon a small number of patients. As is
the case with all biopharmaceutical products under development,
results from future studies with more data may show less favourable
outcomes. DATASOURCE: Transgene CONTACT: Patrick Squiban, MD, VP,
Medical and Regulartory Affairs, Transgene, +33-3-88-27-91-73;
Michael Long, Cohn & Wolfe, +1-415-365-8523; Tiphaine
Hecketsweiler of Image 7, +33-1-53-70-74-70, both for Transgene Web
site: http://www.transgene.fr/
Copyright